Neoadjuvant immunochemotherapy has revolutionized the treatment of non-small cell lung cancer.
However, it presents significant surgical challenges, leading to controversy over the feasibility and safety of minimally invasive surgery.
This study aims to assess the adequacy of minimally invasive surgery and preoperatively predict its difficulty for non-small cell lung cancer after neoadjuvant immunochemotherapy.
